SecBot SecBot
8-K ·Filed Feb 25, 2026

CHE

CHEMED CORP
MIXED
Impact 6/10
Horizonweeks Processed8mo ago SEC0000019584-26-000002
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The stock may react positively to the strong 2026 guidance despite weak current results, particularly the significant reduction in Medicare Cap headwinds. Monitor VITAS admissions growth and Roto-Rooter margin recovery as key indicators of execution. The company's share repurchase activity ($174.6M in the quarter) provides additional support.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$396.63
T+0 close · Feb 25, 2026 · via day close
Latest settled
+11.33%
T+60 · $441.55
Vs SPY
+3.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $396.63entry
  2. T+1 · 9mo ago +3.37%α +3.83% · $410.01
  3. T+5 · 9mo ago +3.92%α +5.04% · $412.16
  4. T+20 · 8mo ago −6.22%α +0.18% · $371.95
  5. T+60 · 6mo ago +11.33%α +3.57% · $441.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemed Corp reported flat Q4 2025 revenue of $639.3 million but a 9% decline in GAAP EPS to $5.48. The VITAS segment showed modest growth in net patient revenue (1.9%) and admissions (6%), while Roto-Rooter revenue declined 3.7%. The company provided strong 2026 guidance with EPS expected to grow to $23.25-$24.25, driven by a significant reduction in Medicare Cap billing limitations and projected revenue growth across both segments.

Key Financial Metrics

Revenue
$639.3M
0.0% YoY
Adj. EPS
$6.42
GAAP: $5.48
Free Cash Flow
$325.5M

Key Facts

  • Q4 2025 revenue was $639.3 million, essentially flat YoY
  • GAAP EPS was $5.48, down 9% YoY; Adjusted EPS was $6.42, down 6% YoY
  • VITAS net patient revenue increased 1.9% to $418.8 million with 6% growth in admissions
  • Roto-Rooter revenue decreased 3.7% to $220.6 million with significant margin compression
  • 2026 guidance projects EPS of $23.25-$24.25 (up from $21.55 in 2025) with VITAS revenue growth of 5.5%-6.5% and Roto-Rooter growth of 3.0%-3.5%
  • Medicare Cap billing limitations expected to decrease to $9.5 million in 2026 from $27.2 million in 2025

Financial Impact

Revenue flat at $639.3M, EPS down 9% to $5.48, but 2026 guidance shows significant improvement with EPS expected to grow to $23.25-$24.25

revenueepsguidancemargins

Segment Breakdown

SegmentRevenueGrowth
VITAS$418.8M+1.9%
Roto-Rooter$220.6M-3.7%

Risk Factors

  • Roto-Rooter segment showing declining revenue and significant margin pressure
  • Execution risk on the optimistic 2026 guidance, particularly the margin improvement targets
  • Concentration risk in VITAS segment's Medicare reimbursement policies

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000019584-26-000002
Document: che-20260225x8k.htm0000019584-26-000002
Document: 0000019584-26-000002-index-headers.html0000019584-26-000002
Document: 0000019584-26-000002-index.html0000019584-26-000002
Document: 0000019584-26-000002.txt0000019584-26-000002

Track record

19 reports on CHE

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.86% at T+5 after the Oct 27, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $528.05 to $548.20 Now $549.45 +4.05% ▲ +3.82% +1.22% vs SPY
  2. Nov 5, 202611d ago Insider Cluster Bearish 4/10 Entry $533.77 to $550.20 Now $549.45 −2.94% ▼ −3.08% +0.21% vs SPY
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $533.65 to $544.49 Now $549.45 +2.96% ▲ +2.03% +2.62% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
  5. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  6. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
  7. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $512.98 to $534.72 Now $549.45 +7.11% ▲ +4.24% +4.80% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 1/10 Entry $502.90 to $498.25 Now $549.45 +9.26% ▼ −0.92% −2.23% vs SPY
  9. Sep 16, 20268w ago Press Release Neutral 4/10 Entry $505.97 to $495.65 Now $549.45 +8.59% ▼ −2.04% −2.64% vs SPY
  10. Aug 24, 202612w ago Insider Cluster Neutral 3/10 Entry $541.34 to $518.71 Now $549.45 +1.50% ▼ −4.18% −4.65% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026